Drug Profile
AR 08
Alternative Names: AR-08Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class Behavioural disorder therapies
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Psychiatric disorders
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Vasomotor symptoms
Most Recent Events
- 28 Jun 2022 Discontinued - Phase-II for Vasomotor symptoms in USA (PO) (Azurity Pharmaceuticals pipeline, June 2022)
- 27 Dec 2019 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (PO) (Arbor Pharmaceuticals website, December 2019)
- 11 Feb 2015 Arbor Pharmaceuticals terminates a phase II trial in Vasomotor symptoms in USA (NCT02049164)